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Introduction
Parkinson’s disease (PD) is a
neurodegenerative disease of the
dopaminergic neurones in the substantia
nigra and is thought to be caused by a
complex interaction between genetic
and environmental risk factors.
The current NICE Clinical
Guideline 35 (CG35), which 
is due to be updated in 2017, 
defines PD as:
“A progressive neuro-
degenerative condition
resulting from the death of the
dopamine-containing cells of the
substantia nigra. The diagnosis is
primarily a clinical one based on 
the history and examination. 
“People with PD classically present
with the symptoms and signs associated
with parkinsonism, namely hypokinesia
(i.e. poverty of movement), bradykinesia
(i.e. slowness of movement), rigidity and
rest tremor.”
PD potentially affects all muscle groups
to an extent where it limits daily activities
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This module is suitable for use by community pharmacists as part of 
their continuing professional development. After reading this module 
in the magazine or online, complete the scenarios and post-test at
www.pharmacymagazine.co.uk and include in your personal learning log.
CPD is one aspect of professional development and can be considered
alongside other activities for inclusion in your RPS Faculty portfolio.
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GOAL
To enable pharmacists to provide
proactive medicines optimisation
services for people with Parkinson’s
disease (PD) and their carers.
OBJECTIVES
After studying this module you should be able to:
• Recognise early signs and symptoms associated
with possible PD and signpost appropriately
• Identify medicines which may be harmful in PD
• Plan and conduct a MUR for a person taking
levodopa or a dopamine agonist.
Welcome to the two hundred and forty first module
in the Pharmacy Magazine Continuing Professional
Development Programme, which looks at supporting
patients with Parkinson’s disease.
Journal-based educational programmes are an
important means of keeping up to date with your
clinical and professional knowledge. Completion of 
this module will contribute to the nine pieces of CPD
that must currently be recorded a year. 
Before reading this module, test your existing
understanding of the subject by completing the pre-test
at www.pharmacymagazine.co.uk. Then, after studying
the module in the magazine or online, work through 
the learning scenarios and post-test on the website to
check your answers. Record your learning using your
personal Pharmacy Magazine online log.
The RPS Faculty and advancing your
professional development
Pharmacy Magazine’s CPD programme can form part of your
professional development, providing you with essential
knowledge and skills. It can also be considered alongside
other activities for inclusion in your RPS Faculty portfolio. 
The RPS Faculty is a professional recognition programme
for all pharmacists in all sectors at all stages of their career
and involves assessment of a practice-based portfolio that
recognises their professional development.
This allows you to demonstrate to others your level of
attainment and stage of advanced practice. It also helps you
to identify what you need to know at different stages of your
career. Start your Faculty journey by accessing the portfolio
and tools at www.rpharms.com/Faculty.
This module is also online at 
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First in professional development
forthismodule
Supporting patients with
Parkinson’s disease
Contributing author: Dr Denise Taylor, senior
lecturer in clinical pharmacy, Department of
Pharmacy and Pharmacology, University of Bath
and also encompasses autonomic
dysfunction (constipation, erectile and
urinary dysfunction, hypotension and
dizziness), neuropsychiatric conditions
(depression, dementia, hallucinations and
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psychosis), pain, lethargy/fatigue, and has 
a major impact on quality of life for the
individuals and their carers and families. 
Increasingly recognised is the presence of
prodromal symptoms occurring up to 20 years
prior to diagnosis. The commonest early
presenting symptoms in the 10 years before 
PD are constipation, fatigue, dizziness, hypo-
tension, erectile and urinary dysfunctions. 
Later onset symptoms (occurring four to five
years before diagnosis) are tremor, balance 
and rigidity. 
Depression occurred in 10 per cent of all
people diagnosed with PD two years prior to 
a diagnosis being made, compared to only 4 
per cent in people without a PD diagnosis.
Prevalence 
Parkinson’s disease is the fourth commonest
neurological condition in the UK behind stroke,
all forms of dementia and epilepsy. In terms of
progressive neurodegenerative diseases it is
second only to Alzheimer’s disease.
In the UK PD affects between six to 11 people
in every 6,000 (the average size of a general
practice list) and, on average, there will be five
to eight people on PD medication in every
community pharmacy. There is a family history
of PD in 20-30 per cent of cases but only 5 per
cent of these are attributed to single gene
defects. Having a genetic risk present does not
mean PD is inevitable.
Parkinson’s is rare below the age of 50 years 
– such cases are known as juvenile PD and
account for only 5 per cent of all PD cases – 
but affects 1 per cent of the population over 
65 years, rising to 2 per cent in people over 80
years. Of note, 50-80 per cent of people with 
PD may develop Parkinson’s disease dementia
(PDD), although this seems more related to
increasing age than PD itself. 
Neuropathological changes
During the disease process there is progressive
loss of dopaminergic cells from the substantia
nigra pars compacta in the brain stem,
projecting into the striatum (caudate nucleus
and putamen-basal ganglia). This cell loss
results in decreased dopamine (as well as
serotonin and GABA) in the striatum. PD is not
caused by an imbalance of acetylcholine and
dopamine as once thought; its underlying
mechanism is more complex than that. 
The basal ganglia controls muscle tone and
provides smooth muscle voluntary movements.
PD symptoms present as impairment in carrying
out learned voluntary actions (see Table 1) when
80 per cent of dopaminergic cells are lost. 
Every person with PD has a different set of
signs and symptoms (see Table 2), so care and
treatment needs to be individualised. 
Other signs associated with PD may be
present, but these are not diagnostic in their
own right. They include: 
• Hypomimia (reduced facial expression)
• Micrographia (very small hand writing that
slopes off the page)
• Impaired blinking
• Reduction in speech volume
• Autonomic abnormalities
• Difficulty swallowing/excess saliva and/or
drooling
• Sleep dysfunction
• Neuropsychiatric disturbances
• Gait abnormalities. 
People may also complain of pain, tiredness,
depression and constipation.
Medication-induced parkinsonism
Any medication that blocks the action of
dopamine can cause parkinsonian-like
symptoms (tremor, rigidity, bradykinesia,
dystonia), which account for 7 per cent of
people presenting with suspected PD (see Table
3). These medication-induced effects respond
poorly to levodopa therapy. Dependent on the
agent, slow withdrawal is recommended, with
60 per cent of patients recovering in two months,
but others may take up to two years. 
A number of medicines can cause tremor and
these should not be prescribed for people with
PD unless agreed by a specialist neurologist, 
and then used at the lowest possible dose for
the shortest period of time.
Non-pharmacological treatments 
and support services
These are extremely important for people 
with PD at any stage of their disease. 
Treatments (whether pharmacological or 
non-pharmacological) should be tailored to
individual need. For example, physiotherapy
aids retention of muscle strength and mobility;
occupational therapy supports maintenance of
daily activities (washing, dressing, tips for un-
freezing); speech and language therapy enables
communication; patients may need help with
swallowing (eating and drinking); and social
services are necessary for access to disability
and financial support. 
Staging in Parkinson’s disease 
There are four stages to PD: 
• Establishing the diagnosis
• Early or maintenance PD
• Complex or later PD
• Palliation. 
Treatments do not cure or halt progression, 
but they do improve quality of life.
Early PD
In early PD the aim is to preserve dopaminergic
function for as long as possible by using
dopamine supplementation. Levodopa prep-
arations, non-ergot derived dopamine agonists
and MAOI-B inhibitors are all first-line options
Pharmacy Magazine CPD modules
provide you with knowledge to help you to develop and advance 
your practice and can be recorded in your Faculty portfolio. 
Start your journey now by accessing the Faculty portfolio, tools 
and resources atwww.rpharms.com/Faculty.
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Table 1: Learned voluntary actions
Walking
Washing
Household   
chores
Bathing
Answering 
the phone
Driving
Dancing
Enjoying hobbies
Rising from a   
chair
Eating
Talking
Dressing
Shopping
Gardening
Working
Having sex
Turning over 
in bed
Getting out 
of bed
Cooking
Climbing stairs
Using public 
transport
Going to the 
toilet
Cleaning teeth
Playing sport
Writing
Socialising
Fine movement 
activities
Examples of learned voluntary actions are:

Table 2: Associated symptoms of PD
Dribbling/drooling
Swallowing
Incontinence
Constipation 
Pain (muscle spasm)
Freezing
Depression
Slowness 
Anxiety
Tremor
Insomnia                                                     
Behaviour
Confusion
Nightmares
Memory
Hallucinations
Common problems would include:
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in early PD. The choice is dependent on the
individual circumstances (e.g. age, preference,
tolerability), and after the short and long-term
benefits and drawbacks of each class of
medicine have been explained to the patient. 
Historically, levodopa with a decarboxylase
inhibitor (DCI) has been the gold standard of
treatment, but tolerance to levodopa occurs
over time. Tolerance is estimated at 10 per cent
year-on-year, making it inappropriate to use
first-line in younger patients as it will be
ineffective within 10 years. 
Anticholinergic agents, amantadine and beta-
blockers are not recommended in early PD due
to lack of evidence or limited efficacy. (See Table
4 for treatment options.)
Complex or later PD
After five to 10 years of taking a levodopa
preparation, between 50-70 per cent of people
experience ON or OFF episodes. 
An ON episode is when a person with PD can
perform activities of daily living as normal for
them; OFF is when they completely freeze and
voluntary movement is difficult or impossible.
This can be extremely frightening and may
cause a great degree of anxiety and concern 
for the person with PD and his/her family. 
These fluctuations in symptom control may not
necessarily relate to the timing of medicines
administration.
Eighty-five per cent people taking levodopa
experience ‘wearing off’ of drug efficacy, with 
37 per cent experiencing a sudden ON/OFF and
34 per cent a delayed ON response to their 
usual treatment.
In later PD an adjuvant agent is required to
reduce complications and improve quality of
life. There is no single adjuvant agent of choice
so selection is based on patient preference after
the short and long-term benefits and drawbacks
of each class of medicine have been explained 
to them and what they had been originally
prescribed is taken into account.
If a person has been on a levodopa
preparation first-line, then either a COMT
inhibitor or a non-ergot derived dopamine
agonist could be introduced. In the latter case,
the dose of levodopa must be reduced to
prevent dyskinesia and neuropsychiatric effects,
such as hallucination and psychosis. Conversely,
if a person has been on a non-ergot derived
dopamine agonist first-line, then either a levo-
dopa preparation or a COMT inhibitor could be
added. (See Table 5 for treatment options.)
Palliative stage
This stage is characterised by a lack of efficacy 
of medication, increasing side-effects and
movement disorders. Neuropsychiatric
symptoms and/or dementia may be present 
with problems in swallowing, eating, commun-
ication or completing activities of daily living.
The aims at this stage are to reduce
unnecessary medication, and address freezing
episodes, postural instability, falls, mood
disturbance and dementia (rivastigmine is
licensed for Parkinson’s disease dementia),
while facilitating communication and
individualised patient care and carer support.
You can complete this module online at
pharmacymagazine.co.uk and record your
learning outcomes and the impact on your
practice in your personal learning log
One of your patients with early Parkinson’s disease has
had a minor accident while driving. His carer is very
concerned. What advice would you give and what are
your responsibilities in terms of protecting other road
users by informing the DVLA? (See dvla.gov.uk/
medical.aspx for further information.)

Reflection exercise 1
If someone is experiencing an episode of freezing, 
there are ways in which movement can be re-started.
This will depend on patient experience and choice. 
Often verbalising the action a person wants to do 
(e.g. lift the foot forward, take a step and walk through
the door) may help them to do this. Singing, whistling 
a tune, counting or stepping over a carer’s foot or
holding a stick and tapping the foot they want to move
may also help. 
Never pull or push someone as they could fall and
injure themselves. Remember: this situation can be
very frightening for an individual and they may need
lots of gentle, calm reassurance.

Counselling point
Parkinson’s disease can be hugely debilitating and have a major impact on quality of life

Table 3: Medicines associated with
parkinsonism
Anti-emetic
Antipsychotics
Antihypertensives
Causality unproven
Metoclopramide,
prochlorperazine, cinnarizine
First generation: dose
dependent – avoid haloperidol
Second generation: dose 
dependent effects – avoid.
Clozapine least association with 
movement abnormalities
Calcium channel blockers
NSAIDs, captopril, amiodarone,
phenytoin, valproate, lithium,
oral contraceptives, SSRIs
Medication class Example
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Pharmacological agents:
Levodopa + decarboxylase inhibitor
To treat the symptoms of PD the amount of
dopamine available in neuronal synapses 
needs to be increased. Exogenous dopamine 
is rapidly broken down in the peripheral
circulation by decarboxylase and catechol-O-
methyl transferase (COMT) enzymes. To ensure
the maximum amount is able to cross the
blood-brain barrier, levodopa (LD) is generally
combined with a decarboxylase inhibitor 
(DCI) (carbidopa in Sinemet [co-careldopa] 
or benserazide in Madopar [co-beneldopa].
These agents are as effective as each other,
but one may be preferable to an individual. 
It is imperative that they are always taken 
as prescribed, as even small errors in dose or
timing may affect the well-being of the patient
for some days. If in doubt, pharmacists should
always ask the person for confirmation that they
are dispensing their usual medication.
If a dose is missed in early PD, little effect may
be seen on movement, but in later PD dopamine
storage is impaired so the effects will be greater. 
In early PD levodopa preparations are taken
with or after food to minimise nausea and
vomiting (domperidone is ineffective), but in later
PD doses are taken before food so absorption is
not impaired by the presence of proteins. 
People with PD are encouraged to leave
protein-rich meals to later in the day after they
have taken the majority of their levodopa doses
in order to improve its absorption as well as 
the more predictable effects on PD symptoms 
at any stage.
Immediate release preparations
Levodopa immediate release preparations
generally have a short half-life so require three
to four times daily dosing to a maximum of 
five doses in 24 hours. Only immediate release
preparations should be prescribed in early PD. 
Levodopa preparations are started at 50mg
once daily, increasing every three to four days
until a dose regimen of 50mg three times daily
is reached. This can then be titrated (when
appropriate) to 100mg three times daily. 
This slow titration is to avoid side-effects,
especially nausea, postural hypotension and
neuropsychiatric effects. 
Pharmacy teams should be able to anticipate
side-effects of levodopa and highlight these 
to individual patients. Interactions with other
medicines should also be predicted and avoided
where possible.
Controlled release preparations
In the past controlled release preparations were
often used first-line in the hope of delaying
tolerance to levodopa, but this is no longer
considered appropriate and is strongly advised
against. Controlled release preparations should
only be initiated in complex PD by a specialist,
in order to simplify medication regimens. 
The bioavailability of dopamine from controlled
release preparations is less than that from
immediate release products (60-70 per cent
compared to 90-100 per cent), and this
necessitates careful levodopa dose increases 
to compensate.  
Bioavailability of controlled release products
is increased when administered with food, but
decreased if antacids have been taken.
The nomenclature of these preparations can
be confusing and care should always be taken
by pharmacists and pharmacy technicians when
dispensing them to ensure the correct product
has been selected.

Table 4: Pharmacological options in early PD
Agent
Levodopa & DCI
Dopamine
agonist (DA)
MAOI-B
inhibitor
Anticholinergic
Amantadine
Beta-blockers
First choice option?
Yes – good degree of
symptom control.
Immediate release 
ONLY
Yes – moderate degree
of symptom control
Yes – limited degree of
symptom control
No – lack of evidence
and limited efficacy
No – lack of evidence
No – lack of evidence
Side-effects
Increased motor complications
and other adverse effects
Reduced motor complications.
Increased other adverse
effects, especially with ergot
derivatives. Also associated
with impulsive control
disorder and narcolepsy 
Reduced motor complications.
Increased other adverse
effects
Cause neuropsychiatric side-
effects, dry mouth, blurred
vision, urinary retention,
exacerbation of glaucoma
and constipation.
NOT for use in elderly 
Ankle oedema, confusion,
livedo reticularis,
hallucinations
Symptomatic treatment of
postural tremor in PD only
Special cautions
Keep dose as low as possible to reduce
development of motor complications.
Maximum amount 800mg daily in
maximum of five daily doses
Titrate to clinically effective dose. 
If side-effects prevent this, another agonist
should be tried or a medicine from another
class. If an ergot-derived agonist, monitor
renal function and ESR, and take chest 
x-ray before and annually 
Slows breakdown of DA in striatum,
boosting levels & prolongs LD half-life.
Apoptosis form of programmed cell death
thought to be important in several neuro-
degenerative disorders including PD.
Blocks conversion MPTP to MPP+.
Wafer selegiline (Zelapar 1.25mg = 10mg
oral). Not metabolised by buccal to 
l-amphetamine by 90 per cent. On tongue
before breakfast – no drinking/eating 
for five minutes. Contraindication: any
antidepressant (washout if necessary)
Last dose at 2pm
Blood pressure/pulse measurement
How many people with Parkinson’s disease are
currently on your PMR? When was the last time you
invited them for a medicines use review?

Reflection exercise 2
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Non-ergot derived oral dopamine
agonists 
Dopamine agonists were originally developed as a
levodopa-sparing agents in early PD but the reality
of delaying the need for levodopa preparations in
the long-term has not been realised. 
The original ergot-derived dopamine agonists
(bromocriptine, cabergoline, pergolide) are
associated with potentially severe fibrotic
adverse effects requiring increased monitoring,
and are no longer first-line options in this class.
The recommended non-ergot derived dopamine
agonists are now ropinirole, pramipexole and
rotigotine. 
Dopamine agonists bind directly to post-
synaptic receptors to give a more reliable and
sustained biological response and therefore,
theoretically, should be more effective in early
PD. They are not stored by degenerating
dopaminergic neurones and so reduce
dopaminergic turnover and resultant free radical
production at the synapse. They also have a
longer half-life, resulting in less frequent dosing
schedules.
The dopamine receptor sub-type specificity
varies between agents, so if there is little gain
with one agent, another should be tried. 
Apomorphine is a parenteral dopamine
agonist given by continuous subcutaneous
infusion or intermittent subcutaneous ‘rescue’
injection for OFF or freezing episodes. It is
powerfully emetogenic and requires at least 
48 hours’ pre-treatment with domperidone. 
As determining the dose requires stopping PD
treatment overnight, apomorphine is only
started in specialist centres. There is evidence
for eight years of continuous usage, but it 
is also associated with hypotension and
development of skin nodules.
Adverse effects include nausea, dyskinesia,
orthostatic hypotension, somnolence (sudden
sleep attacks with ropinirole and pramipexole),
dizziness and psychiatric disturbances including
impulse control disorders such as pathological
gambling, hypersexuality and binge eating. 
(It should be remembered that dopamine 
is involved in the reward pathway of 
addiction.) 
Monoamine oxidase B (MAOI-B)
inhibitors
For some years it was thought that selegiline,
due to its MAOI-B activity, had a neuro-
protectant role and an anti-apoptotic effect
(preventing cell death), hence its use as first-line
treatment in early PD to try and prevent the
need for early levodopa therapy. However
current NICE and SIGN guidance is very clear
that MAOI-B inhibitors should not be used as
neuro-protectant therapy for people with PD
except if part of a clinical trial.
The place of MAOI-B inhibitors (selegiline 
and rasagiline) in PD is as a first-line treatment
option (less effective than levodopa or
dopamine agonists) or as an adjunct to therapy
One of your patients with Parkinson’s disease has
routine surgery booked for a knee replacement. She is
very concerned about how she can ensure she takes her
medications at the times she needs them and not at the
usual ward medication round times. What information,
support and assurance can you offer her?

Reflection exercise 3

Table 5: Pharmacological options in later PD
Agent
Dopamine
agonist
COMT inhibitor
MAOI-B
inhibitor
Amantadine
Apomorphine
Modified-
release
preparation of
levodopa+DCI
First choice option?
Yes – moderate degree of symptom
control
Yes – moderate degree of symptom
control
Yes – moderate degree of symptom
control
Non-significant result
No – limited degree of symptom control
No – can be used but not first option
Effects
Reduced motor complications.
Increased other adverse effects
May reduce motor fluctuations
Reduced motor complications
(dyskinesias).
Increased other adverse effects
Reduced motor complications
Can reduce motor fluctuations
Monitoring
Titrate to clinically effective dose. If
side-effects prevent this, try another
agonist or a medicine from another class
COMT inhibitors should be taken 20
minutes prior to levodopa for best effect,
but adherence is difficult. A triple
combination of levodopa, carbidopa and
entacapone should be offered
Special cautions*
Ergot agonist derivatives: annual
monitoring of renal function, ESR and
chest x-ray
Tolcapone should only be used after
entacapone has failed or has intolerable 
side-effects. Liver function tests required
every two weeks in the first year, then
every four weeks for six months and every
eight weeks thereafter. (Risk of fulminant
liver failure)
Initiation restricted to expert units with
facilities for monitoring
Intermittent injections may reduce OFF time in people with severe motor
complications. Continuous subcutaneous infusion may reduce OFF time and
dyskinesias in people with severe motor complications. Increased other
adverse effects
Ensure timing intervals.  
Be aware of signs of excess dopamine when adding or changing therapy
* Never withdraw antiparkinsonian medication abruptly as this can lead to akinesia or neuromalignant syndrome, both potentially fatal.
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to reduce motor fluctuations in complex or 
later PD. Selegiline is metabolised to meth-
amphetamine and amphetamine, producing
euphoria as an adverse effect. It also causes
psychiatric disturbance and increased risk of all-
cause mortality. With insomnia another adverse
effect, oral dosing is prescribed before 2pm.
Licensed buccal dosage forms by-pass this
metabolic route and subsequently the
associated adverse effects.
Catechol-O-methyltransferase 
(COMT) inhibitors
To understand the place of catechol-O-
methyltransferase (COMT) inhibitors, it is
important to understand the metabolism of
levodopa. In the absence of a decarboxylase
inhibitor (DCI), 70 per cent of levodopa
undergoes decarboxyation and 10 per cent by
COMT. In the presence of a DCI, an increased
proportion is metabolised by the COMT route.
By adding in a COMT-inhibitor, the central and
peripheral availability of levodopa is increased,
delaying its elimination and prolonging the
duration of action. 
There are two licensed COMT inhibitors –
entacapone and tolcapone – although tolcapone
is not a first-line choice due to its association
with precipitating life-threatening
hepatotoxicity. Entacapone is therefore the
preferred agent and is given at the same time 
as a dose of levodopa with a decarboxylase
inhibitor to a maximum of 2g daily. It can colour
urine reddish-brown and has a number of side-
effects including cardiac, neuropsychiatric and,
rarely, hepatic side-effects. 
Important considerations with PD
medication
PD is a fluctuating, debilitating disease and the
efficacy of pharmacological treatments also
fluctuates, as does the response to treatment. 
It is important to remember that trapped within
an uncooperative body is a cognitively intact
person.
The clinical features of PD profoundly affect
an individual’s ability to communicate and can
prejudice how people communicate with them
because the altered body language and facial
expressions of people with PD can seem
threatening to others. 
With 55 per cent of communication via body
language, 38 per cent dependent on tone and
volume, and only 7 per cent on the words
spoken, it is important to adapt your
communication skills to help the person
communicate effectively with you. Due to
reduced speech volume, conversations may be
better in a quiet consultation room rather than
at the medicines counter.
It is extremely important to remember that
antiparkinsonian medicine should never be
withdrawn abruptly or allowed to fail suddenly
due to lack of absorption (e.g. in gastroenteritis
or abdominal surgery) because of the risk of
acute akinesia (total loss or impairment of the
power of voluntary movement for the person,
akin to paralysis) or neuroleptic malignant
syndrome occurring.
People with PD who are hospitalised, awaiting
surgical procedures or admitted to care homes,
should have their medication given to them 
at the times appropriate to them and not be
constrained by the organisation’s routine. 
Self-medication should be a preferred option. 
Medicine doses or timing should be adjusted
by/or only after discussion with a specialist. 
This may be a consultant neurologist, elderly
care physician, Parkinson’s nurse or other
suitably trained healthcare professional. 
Parkinson’s UK has published guidance for
both community and hospital pharmacists on
the most appropriate use of PD medicines. 
It is important to be aware of the key
recommendations. (See parkinsons.org.uk/
professionals/resources/key-information-
community-pharmacists-booklet.) 
Information gathering
Parkinson’s UK would like community
pharmacists to ask patients the five questions
below, rate the answers and then provide the
patient and their specialist with a copy of the
outcome. You could do this during a MUR.
1. When was your last hospital appointment
with a Parkinson’s specialist?
Within the last six months ..................................0 
Within the last 12 months...................................5 
More than 12 months .......................................15 
Have never seen a specialist for the
management of my Parkinson’s .......................20
vi CPD NOVEMBER 2015 PHARMACY MAGAZINE THIS CPD MODULE PLUS PRE-TEST AND POST-TEST IS ONLINE AT WWW.PHARMACYMAGAZINE.CO.UK PULL OUT AND KEEP
Could you signpost a person newly diagnosed with
Parkinson’s disease to local support groups for people
with the condition and their families? Visit the
Parkinson’s UK website (parkinsons.org.uk) and NHS
Choices (nhs.uk/conditions/Parkinsons-disease/Pages/
Introduction.aspx). Use these to create your local list.
Patient access to carer support and social services may
need referral by a GP.

Reflection exercise 4
Computer artwork of neurons (green) affected by Lewy bodies (orange) in the brain of someone with PD
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2. How would you rate the control of your
Parkinson’s symptoms at the moment?
Well controlled ....................................................0 
Somewhat controlled ..........................................5 
Poorly controlled ...............................................15 
Not controlled ...................................................20
3. Do you remember to take your medication
every time?
Yes........................................................................0 
Misses the occasional dose (one a week) ..........5 
Misses regular doses (one a day) .....................15 
Not compliant – I do not have a clear
understanding of my medication regimen .......20
4. Do you ever take additional Parkinson’s
medication over and above what your
specialist has advised?
No, never .............................................................0 
Infrequently .........................................................5 
Most of the time ................................................15 
All of the time ....................................................20 
5. Are you experiencing any new motor
symptoms (e.g. freezing, increased tremor 
or gait problems) since your last hospital
appointment?
No ........................................................................0 
Not sure ...............................................................5 
Occasionally .....................................................15 
Yes......................................................................20 
Total score from assessment questions =
outcomes of total score
0-15 Satisfactory review. No action necessary
15-30 Direct to local Parkinson’s nurse
30+ Intervention required. Refer to GP for
onward referral to Parkinson’s specialist
50+ Urgent intervention required. Patient to 
see GP as soon as possible for referral to
Parkinson’s specialist.
A medicines use review could also cover the
following areas:
• Handling of medication packaging
• Loss of smell: may affect appetite
• Dry mouth: may impair eating/communication
• Visual disturbances: affect mobility and
increase risk of falls 
• Falls: any fall should be investigated and the
person referred appropriately
• Sleep/mood disturbance: refer for treatment
• Daytime hypersomnolence: refer for review
• Memory/dementia: refer for specialist advice
• Pain: this is from muscle spasms in dystonias
and dyskinesias, refer for treatment;
physiotherapy may also help.
Other common issues in PD include mood and
autonomic symptoms. The autonomic nervous
system works to control the unconscious or
automatic functions of heart rate, digestion,
breathing rate, perspiration, urination and
sexual arousal. These issues may emerge during
a MUR discussion. If they do, the patient should
be signposted and/or referred for specialist
review. 
As swallowing difficulties increase over time
and the adverse effects of PD medication
become less tolerable, there may be a need to
change the formulation of a medication to one
that is more suitable for the individual.
Some people may need different formulations
of the same agent, e.g. a dispersible levodopa
preparation with a standard release preparation
taken in the morning to aid mobility and/or 
a controlled release preparation at night to
prevent OFF periods. 
The manufacturer’s guidance in the SPC
should always be used for conversion rates
when changing between formulations to take
into account differing rates of absorption.
Generic drugs are available but absorption rates
may differ, so people should be titrated and
maintained on the same brand. 
Cautions, contraindications and common
side-effects should always be checked to ensure
patient safety.
Pharmacy Magazine’s CPD modules are available on Cegedim Rx’s PMR systems, Pharmacy
Manager and Nexphase. Just click on the ‘Professional Information & Articles’ button within
Pharmacy KnowledgeBase and search by therapy area. Please call the Cegedim Rx helpdesk 
on 0844 630 2002 for further information.
This module is also online at 
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• Key information for community pharmacists: parkinsons.org.uk/sites/default/files/publications/download/
english/b0148_ keyinformationforcommunitypharmacists.pdf
• NICE Clinical guideline 35, 2006: nice.org.uk/guidance/cg35/evidence/cg35-parkinsons-disease-full-guideline2
• NICE Pathways for Parkinson’s disease: pathways.nice.org.uk/pathways/parkinsons-disease
• Kearney D, Dunsmure L. Parkinson’s disease management. Clinical Pharmacist 2011 (3) 368-373
• Blochberger A, Jones S. Parkinson’s disease clinical features and diagnosis. Clinical Pharmacist Vol 3 December 2011
p361-366
• Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and 
all-cause mortality in older adults: A systematic review and meta-analysis. British Journal of Clinical Pharmacology
Volume 80, Issue 2, pages 209-220,  August 2015. DOI: 10.1111/bcp.12617
• Nannor N. Understanding essential tremor. Pharmacy professional. March 2010. P6-41
• NICE Clinical Knowledge Summaries for PD: cks.nice.org.uk/parkinsons-disease 
• SIGN 113. Diagnosis and pharmacological management of Parkinson’s disease. A national clinical guideline. 
January 2010. sign.ac.uk
• bestpractice.bmj.com/best-practice/monograph/147.html
• Hypersalivation and oral glycopyrronium bromide: nice.org.uk/advice/esuom15/chapter/key-points-from-the-evidence

Further reading and useful resources
Now that you have completed this module, invite two
patients with PD for a MUR and use some of the tips you
have learnt here. If the patient cannot come to see you
at the pharmacy, consider requesting permission to do a
MUR by telephone.

Reflection exercise 5

Autonomic symptoms in PD
Symptoms
Incontinence
Erectile dysfunction
Dysphagia 
(impaired swallowing)
Weight loss
Orthostatic hypotension
Excessive sweating
Sialorrhoea
Constipation
NICE guidance & comments
Highly anticholinergic agents may impair cognitive function and worsen constipation
and dry mouth
Affects intimate relationships 
This may affect eating and lead to weight loss and impaired verbal communication skills
Refer for nutritional advice
Can be exacerbated by medication treatment and lead to falls
Embarrassing for the individual
Embarrassing for the individual
Ensure a stimulant laxative and/or softener is prescribed as appropriate
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PARKINSON’S DISEASE
1. What diagnostic test can
be used to identify PD?
a. A CT scan 
b. A MRI scan 
c. Presence of a genetic missense 
d. None. Diagnosis comprises
the history of symptom onset,
exclusion of other causes and
baseline imaging
2. Which is NOT a first choice
option in early PD?
a. Dopamine agonist 
b. Levodopa and DCI
c. Beta-blocker
d. MAOI-B inhibitor
3. Which of the following 
is NOT recommended 
as a non-ergot derived
dopamine agonist?
a. Ropinirole
b. Pramipexole
c. Cabergoline
d. Rotigotine
4. In relation to PD, which of
the following is FALSE?
a. 20-30 per cent of all cases
have a family history
b. In 20-30 per cent of all cases
there is a familial history and
corresponding genetic cause
c. Five per cent of all cases of PD
are due to a genetic cause
d. Five per cent of all cases of
PD are classed as juvenile
parkinson’s disease
5. Which statement regarding
dopamine agonists is
FALSE? They are:
a. Associated with risk-taking
behaviours 
b. Associated with binge eating
c. Theoretically more effective
in early PD because they bind
directly to post-synaptic
receptors
d. Theoretically more effective
in late stages of PD because
they bind directly to post-
synaptic receptors 
6. As a class of medicines,
which statement is TRUE
about the two levodopa 
+ decarboxylase
preparations?
a. They work in the same way 
b. If one does not prove
clinically effective, neither
will the other 
c. They must never be used in
combination 
d. If severe side-effects occur
with one agent, it is always
worth trying the second agent 
7. Which statement about
selegiline is TRUE?
a. It can be used for its neuro-
protectant effect in early PD 
b. Oral selegiline can cause
euphoria and insomnia
c. The wafer formulation can
cause euphoria and insomnia 
d. Oral dosing is always
prescribed before 11am
8. Which pharmacological
option in later PD should be
taken 20 minutes prior to
levodopa for best effect?
a. Amantadine
b. Apomorphine
c. COMT inhibitors
d. MAOI-B inhibitors
You may need to consult other 
information sources to answer 
the questions.
CPD record
* If as a result of completing your evaluation you have identified another new learning objective, 
start a new cycle. This will enable you to start at Reflect and then go on to Plan, Act and Evaluate.
This form can be photocopied to avoid having to cut this page out of the module. You can also
complete the module atwww.pharmacymagazine.co.uk and record on your personal learning log
November
2015
Pharmacy Magazine
pharmacymagazine.co.uk
viii CPD OCTOBER 2015 PHARMACY MAGAZINE LEARNING SCENARIOS FOR THIS MODULE AT WWW.PHARMACYMAGAZINE.CO.UK PULL OUT AND KEEP
Activity completed. (Describe what you did to increase your learning. Be specific)
(ACT)
Date:      Time taken to complete activity:
What did I learn that was new in terms of developing my skills, knowledge and behaviours? 
Have my learning objectives been met?*
(EVALUATE)
Do I need to learn anything else in this area? (List your learning action points. How do you intend to
meet these action points?)
(REFLECT & PLAN)
How have I put this into practice? (Give an example of how you applied your learning). 
Why did it benefit my practice? (How did your learning affect outcomes?)
(EVALUATE)
Use this form to record your learning and action points from this module on Supporting
patients with Parkinson’s disease or record on your personal learning log at
pharmacymagazine.co.uk. You must be registered on the site to do this. Any training, learning or
development activities that you undertake for CPD can also be recorded as evidence as part of
your RPS Faculty practice-based portfolio when preparing for Faculty membership. So start your
RPS Faculty journey today by accessing the portfolio and tools at www.rpharms.com/Faculty.
You can also record in your 
personal learning log at 
pharmacymagazine.co.uk8
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Now enter your answers online
You no longer have to send your answers away to be marked. Once you are
registered on our website, you can complete the pre- and post-test free of
charge and record your learning outcomes in your personal learning log.
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EGISTE  AT: www.pharmacymagazine.co.uk
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